Old Web
English
Sign In
Acemap
>
authorDetail
>
Charlotte Eltink
Charlotte Eltink
Center for Global Development
Cmax
Pharmacology
Pharmacokinetics
Active metabolite
Darexaban
3
Papers
12
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P‐glycoprotein
2014
Clinical pharmacology in drug development
Dorien Groenendaal
Gregory Strabach
Alberto Garcia-Hernandez
Takeshi Kadokura
Marten Heeringa
Roelof Mol
Charlotte Eltink
Hartmut Onkels
Show All
Source
Cite
Save
Citations (3)
The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4
2013
British Journal of Clinical Pharmacology
Dorien Groenendaal
Gregory Strabach
Alberto Garcia-Hernandez
Takeshi Kadokura
Marten Heeringa
Roelof Mol
Charlotte Eltink
Hartmut Onkels
Show All
Source
Cite
Save
Citations (9)
Co-Administration of YM150, An Oral Direct Factor Xa Inhibitor, and Naproxen Does Not Result In Clinically Relevant Changes to the Pharmacodynamic or Pharmacokinetic Profile of Either Agent
2010
Blood
Marten Heeringa
Alberto Garcia-Hernandez
Takeshi Kadokura
Dorien Groenendaal– van de Meent
Gregory Strabach
Roelof Mol
Charlotte Eltink
Hartmut Heinzerling
Show All
Source
Cite
Save
Citations (0)
1